翻訳と辞書 |
Chlorproguanil hydrochloride-dapsone-artesunate : ウィキペディア英語版 | Chlorproguanil hydrochloride-dapsone-artesunate Chlorproguanil-dapsone-artesunate (abbreviated CDA) is a new antimalarial treatment that entered Phase III clinical trials in 2006. It consists of chlorproguanil hydrochloride, dapsone, and artesunate. (It can also be interpreted as Lapdap+artesunate). It is being compared against artemether-lumefantrine (Coartem) and against chlorproguanil-dapsone Lapdap. This drug is being developed in collaboration between GlaxoSmithKline, UNICEF, the World Bank, Medicines for Malaria Venture and the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR), the Liverpool School of Tropical Medicine, and the London School of Hygiene and Tropical Medicine. ==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Chlorproguanil hydrochloride-dapsone-artesunate」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|